All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American Intergroup Study I0129
| Autor: | Jae H. Park, Peter H. Wiernik, Martin S. Tallman, Robert E. Gallagher, Elisabeth Paietta, Jacob M. Rowe, James H. Feusner, Cheryl L. Willman, Lois E. Shepherd, Charles A. Schiffer, Dan Douer, FR Appelbaum, Clara D. Bloomfield, Lynette Zickl |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Acute promyelocytic leukemia Cancer Research medicine.medical_specialty Time Factors Adolescent Long term follow up medicine.medical_treatment Retinoic acid Antineoplastic Agents Tretinoin Intrathecal Article Young Adult chemistry.chemical_compound Leukemia Promyelocytic Acute Internal medicine medicine Humans Child neoplasms Aged Aged 80 and over Chemotherapy business.industry All trans Infant Consolidation Chemotherapy Hematology Middle Aged Prognosis medicine.disease Surgery Survival Rate Oncology chemistry Child Preschool Cytarabine Female Neoplasm Recurrence Local business Follow-Up Studies medicine.drug |
| Zdroj: | Leukemia Research. 37:795-801 |
| ISSN: | 0145-2126 |
| DOI: | 10.1016/j.leukres.2013.03.001 |
| Popis: | We report a long-term follow-up (median 11.8 years) of the First North American Intergroup Study. 379 patients were randomized to induction with ATRA or to chemotherapy. All complete responders (CR) received consolidation chemotherapy, then randomized to 1 year ATRA or observation. 245 patients received ATRA sometime during the study: 195 (80%) achieved a CR. Nine (4.6%) relapsed late (>3 years from CR), the last occurred after 4.6 years; 7 of them were still alive after 5.5–15 years. In APL patients, late relapses are uncommon, and those who sustain CR >5 years can be considered cured. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect